The latest trading day saw Adma Biologics (ADMA) settling at $16.32, representing a -1.03% change from its previous close.

ADMA Biologics performance in the past twelve months has been phenomenal. While the prospects remain sound, the exceptional rally witnessed by the stock might limit any further gain.

Adma Biologics (ADMA) closed at $18.56 in the latest trading session, marking a +1.48% move from the prior day.

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often ...

Here, we discuss four biotech stocks, ADMA, TARS, STOK and CDXC, which have returned more than 50% year to date and have room for more growth in 2025.

Here, we present four biotech stocks, namely SRPT, ADMA, EXEL and ALNY, which most Wall Street analysts are optimistic about. These companies have upside potential for 2025, backed by strong fundament...

ADMA Biologics has performed phenomenally in 2024. Given its strong trajectory, we recommend investors use any dip in the stock price as a buying opportunity.

The mean of analysts' price targets for Adma Biologics (ADMA) points to a 25.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among a...

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often ...

ADMA Biologics is a rapidly growing player in plasma-derived therapies, with a 78% YoY revenue increase and a 1,300% YoY net income boost. The company's key product, ASCENIV, is expected to drive sign...

Here is how Adma Biologics (ADMA) and Addex Therapeutics Ltd. Sponsored ADR (ADXN) have performed compared to their sector so far this year.

If you are looking for stocks that are well positioned to maintain their recent uptrend, Adma Biologics (ADMA) could be a great choice. It is one of the several stocks that passed through our "Recent ...

The average of price targets set by Wall Street analysts indicates a potential upside of 31.3% in Adma Biologics (ADMA). While the effectiveness of this highly sought-after metric is questionable, the...

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employe...

Adma Biologics (ADMA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Adma Biologics (ADMA) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through...

NEW YORK--(BUSINESS WIRE)---- $ADMA #CLASSACTIONLAWSUIT--The law firm of Kirby McInerney LLP is investigating potential claims against ADMA Biologics, Inc. (“ADMA Biologics” or the “Company”) (NASDAQ:...

ADMA Biologics, Inc. (NASDAQ:ADMA ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Skyler Bloom – Senior Director, Business Development & Corporate Strategy Adam Gro...

Adma Biologics (ADMA) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of $0.13 per share. This compares to earnings of $0.01 per share a year ago.

NEW YORK--(BUSINESS WIRE)---- $ADMA #INVESTIGATION--The law firm of Kirby McInerney LLP is investigating potential claims against ADMA Biologics, Inc. (“ADMA Biologics” or the “Company”) (NASDAQ: ADMA...